BACKGROUND: Surface-specific antigens expressed by hematopoietic cells are attractive targets for antibody-mediated immunotherapy. Monoclonal antibodies (mAbs) involve various mechanisms to eliminate target cells, including antibody-dependent cellular cytotoxicity (ADCC)- and phagocytosis (ADCP)-mediated killing through natural killer (NK) and macrophage effector cells bearing FcγRIIIA (CD16). The clinical efficacy of ADCC is particularly impacted by a single nucleotide polymorphism (SNP) found in the gene encoding FcγRIIIA (FCGR3A), which generates a variable distribution of the 158 V/V, F/V or F/F CD16 allotypes (F = phenylalanine, V = valine) in the normal human population. Currently, most patients are not screened for CD16 allotypes, creating the potential to include in their treatment a mAb-based therapy that may have limited benefit. Therefore, it is important to identify CD16 allotypes when considering mAb therapies that require ADCC/ADCP. OBJECTIVE: The objective of this study was to develop a reliable PCR-based assay for classification of human FcγRIIIA allotypes. METHODS: We studied 42 normal human subjects for the incidence of FcγRIIIA-158 polymorphisms using comparative molecular approaches. RESULTS: The results of our study showed 100% accuracy in genotyping by pyrosequencing. In contrast, nested PCR-based allele-specific restriction assay and quantitative PCR techniques proved to be relatively less sensitive and less specific in distinguishing variant genotypes. CONCLUSION: Since the efficacy of the mAb-based targeted immunotherapy may be highly dependent upon the CD16 polymorphism in a given individual, we recommend pyrosequencing for CD16 allotype testing.
BACKGROUND: Surface-specific antigens expressed by hematopoietic cells are attractive targets for antibody-mediated immunotherapy. Monoclonal antibodies (mAbs) involve various mechanisms to eliminate target cells, including antibody-dependent cellular cytotoxicity (ADCC)- and phagocytosis (ADCP)-mediated killing through natural killer (NK) and macrophage effector cells bearing FcγRIIIA (CD16). The clinical efficacy of ADCC is particularly impacted by a single nucleotide polymorphism (SNP) found in the gene encoding FcγRIIIA (FCGR3A), which generates a variable distribution of the 158 V/V, F/V or F/F CD16 allotypes (F = phenylalanine, V = valine) in the normal human population. Currently, most patients are not screened for CD16 allotypes, creating the potential to include in their treatment a mAb-based therapy that may have limited benefit. Therefore, it is important to identify CD16 allotypes when considering mAb therapies that require ADCC/ADCP. OBJECTIVE: The objective of this study was to develop a reliable PCR-based assay for classification of human FcγRIIIA allotypes. METHODS: We studied 42 normal human subjects for the incidence of FcγRIIIA-158 polymorphisms using comparative molecular approaches. RESULTS: The results of our study showed 100% accuracy in genotyping by pyrosequencing. In contrast, nested PCR-based allele-specific restriction assay and quantitative PCR techniques proved to be relatively less sensitive and less specific in distinguishing variant genotypes. CONCLUSION: Since the efficacy of the mAb-based targeted immunotherapy may be highly dependent upon the CD16 polymorphism in a given individual, we recommend pyrosequencing for CD16 allotype testing.
Authors: J Wu; J C Edberg; P B Redecha; V Bansal; P M Guyre; K Coleman; J E Salmon; R P Kimberly Journal: J Clin Invest Date: 1997-09-01 Impact factor: 14.808
Authors: Farrukh T Awan; Rosa Lapalombella; Rossana Trotta; Jonathan P Butchar; Bo Yu; Don M Benson; Julie M Roda; Carolyn Cheney; Xiaokui Mo; Amy Lehman; Jeffrey Jones; Joseph Flynn; David Jarjoura; John R Desjarlais; Susheela Tridandapani; Michael A Caligiuri; Natarajan Muthusamy; John C Byrd Journal: Blood Date: 2009-12-02 Impact factor: 22.113
Authors: Ronald Herbst; Yue Wang; Sandra Gallagher; Nanette Mittereder; Ellen Kuta; Melissa Damschroder; Rob Woods; Daniel C Rowe; Li Cheng; Kim Cook; Krista Evans; Gary P Sims; David S Pfarr; Michael A Bowen; William Dall'Acqua; William Dall'Aqua; Mark Shlomchik; Thomas F Tedder; Peter Kiener; Bahija Jallal; Herren Wu; Anthony J Coyle Journal: J Pharmacol Exp Ther Date: 2010-07-06 Impact factor: 4.030
Authors: Caroline Jochems; James W Hodge; Massimo Fantini; Kwong Y Tsang; Amanda J Vandeveer; James L Gulley; Jeffrey Schlom Journal: Int J Cancer Date: 2017-05-19 Impact factor: 7.396
Authors: Caroline Jochems; James W Hodge; Massimo Fantini; Rika Fujii; Y Maurice Morillon; John W Greiner; Michelle R Padget; Sarah R Tritsch; Kwong Yok Tsang; Kerry S Campbell; Hans Klingemann; Laurent Boissel; Shahrooz Rabizadeh; Patrick Soon-Shiong; Jeffrey Schlom Journal: Oncotarget Date: 2016-12-27